Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Operating Expenses: 2009-2024

Historic Operating Expenses for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $89.6 million.

  • Gyre Therapeutics' Operating Expenses rose 11.22% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.2 million, marking a year-over-year decrease of 47.43%. This contributed to the annual value of $89.6 million for FY2024, which is 50.41% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Operating Expenses of $89.6 million as of FY2024, which was down 50.41% from $180.7 million recorded in FY2023.
  • Over the past 5 years, Gyre Therapeutics' Operating Expenses peaked at $180.7 million during FY2023, and registered a low of $78.3 million during FY2020.
  • Over the past 3 years, Gyre Therapeutics' median Operating Expenses value was $93.1 million (recorded in 2022), while the average stood at $121.1 million.
  • In the last 5 years, Gyre Therapeutics' Operating Expenses spiked by 94.10% in 2023 and then plummeted by 50.41% in 2024.
  • Gyre Therapeutics' Operating Expenses (Yearly) stood at $78.3 million in 2020, then climbed by 21.60% to $95.2 million in 2021, then decreased by 2.25% to $93.1 million in 2022, then spiked by 94.10% to $180.7 million in 2023, then crashed by 50.41% to $89.6 million in 2024.